Collaboration will integrate data into
healthcare provider workflows, supporting remote chronic care and
population health management
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical
Industries Ltd. (NYSE and TASE: TEVA), today announced a new
collaboration with Rimidi, a leading clinical management platform
designed to optimize clinical workflows, enhance patient
experiences and achieve quality objectives.
The collaboration will enable more consumers to have access to
Teva’s Digihaler® system, a digital health platform designed to
enable patients to have more informed treatment discussions with
their healthcare providers through personalized care. The
collaboration will enable healthcare providers to better integrate
patient data into their workflows, supporting proactive remote care
across large populations.
The platform can be used to monitor and manage large populations
by a network of health systems. It can capture objective and
actionable data for asthma patients, thereby creating the mechanism
for personalized care.
Integrated with a broad range of medical devices, including
cellular and Bluetooth-enabled blood-glucose meters, scales, blood
pressure cuffs, pulse-oximeters, insulin dosing pens, and
continuous glucose monitors, Rimidi allows for data aggregation
across multiple devices into a single, streamlined solution that
integrates with the EHR. Digihaler data will be available to
providers as part of Rimidi’s new Respiratory Module, which also
brings in patient-generated data from an integrated pulse oximeter
and relevant data from the Electronic Health Record (EHR) including
medical history, diagnoses and laboratory assessments.
“Digital health platforms will succeed only by seamlessly
integrating multiple data sources into workflows and systems like
electronic medical records (EMR). We believe in building an
ecosystem and are delighted to partner with Rimidi as we seek to
expand the reach of our platform, and continue to shape digital
therapeutics and the integrated care landscape,” said Manny
Montalvo, Senior Vice President, Head of Digital Health &
Innovation at Teva. “We believe that the future of healthcare is in
predictive and preventative care, which is a significant paradigm
shift from the standard of care today. That is why we will focus
our collaboration and our services on facilitating this change, to
help providers deliver better care and help patients manage their
condition.”
“With a rich heritage of delivering innovative medicines,
alongside technology development capabilities, Teva is uniquely
positioned to help the healthcare ecosystem move toward greater
integration of objective health data, and create meaningful
population-scale solutions to help patients and providers. We
envision broad utilization of our platform by consumers, healthcare
providers and other technology organizations. In respiratory care,
our long-term vision is ambitious and clear: harnessing the power
of technology and therapeutics to predict asthma attacks.”
Montalvo continued, “Over the past few years, through a talented
and continuously evolving in-house team we have built a robust
technology arm within Teva to continue exploring ways to improve
patient outcomes. Through our vision for connected therapy, we
strive to be at the nexus between patients, healthcare providers,
technology, and the future of medicine, exploring new ways for
digital health to serve as an economically sustainable solution for
small and large healthcare provider organizations, offering timely,
data-driven solutions to benefit patients. Our hope is that by
working with Rimidi and other capable companies in this space, we
will fulfill our mission of improving the lives of patients, and do
so by improving the health and effectiveness of our healthcare
system – and we’re just getting started.”
“Data from Digital Therapeutics like Teva’s digital inhalers can
provide clinicians with a more holistic picture of their patient’s
health in between doctor visits,” said Lucienne Ide, Founder and
CEO of Rimidi. “To improve patient care and outcomes, the
patient-generated health data doesn’t just need to be available to
clinicians between visits, but merged with other clinical data and
presented within existing EHR workflows and experience.”
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has
been developing and producing medicines to improve people’s lives
for more than a century. We are a global leader in generic,
biosimilar and specialty medicines with a portfolio consisting of
over 3,500 products in nearly every therapeutic area. Around 200
million people around the world take a Teva medicine every day, and
are served by one of the largest and most complex supply chains in
the pharmaceutical industry. Along with our established presence in
generics, we have significant innovative research and operations
supporting our growing portfolio of specialty and biopharmaceutical
products. Learn more at www.tevapharm.com
About Teva Digital Health
Teva aims to be a global leader in personalized, predictive
care, continuously investing in platforms and regulatory-compliant
systems that will help change the nature of digital health as we
know it. Teva’s proprietary software platform Digihaler® –
developed and maintained in-house by a team of research specialists
and programmers – is built into a series of FDA-approved inhalers,
currently marketed in the U.S., and with plans to expand to Europe
in 2023. Learn more at www.Digihaler.com
About Rimidi
Created by doctors, Rimidi’s leading clinical management
platform empowers healthcare organizations to optimize clinical
workflows, enhance patient experiences and achieve quality
objectives. By bringing together clinical decision support, remote
patient monitoring and patient reported outcomes in a unified,
composable, FHIR-based platform, Rimidi supports a broad range of
clinical use cases and institutional priorities across large and
small healthcare organizations. For more information, visit
rimidi.com and follow us on Twitter and LinkedIn.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, which are based on management’s current beliefs and
expectations and are subject to substantial risks and
uncertainties, both known and unknown, that could cause our future
results, performance or achievements to differ significantly from
that expressed or implied by such forward-looking statements. You
can identify these forward-looking statements by the use of words
such as “should,” “expect,” “anticipate,” “estimate,” “target,”
“may,” “project,” “guidance,” “intend,” “plan,” “believe” and other
words and terms of similar meaning and expression in connection
with any discussion of future operating or financial performance.
Important factors that could cause or contribute to such
differences include risks relating to the development and
commercial success of our digihaler products family; our ability to
successfully compete in the marketplace, including our ability to
develop and commercialize biopharmaceutical products, competition
for our specialty products, including AUSTEDO®, AJOVY® and
COPAXONE®; our ability to achieve expected results from investments
in our product pipeline, our ability to develop and commercialize
additional pharmaceutical products, and the effectiveness of our
patents and other measures to protect our intellectual property
rights; our substantial indebtedness; our business and operations
in general; costs and delays resulting from the extensive
pharmaceutical regulation to which we are subject or delays in
governmental processing time due to travel and work restrictions
caused by the COVID-19 pandemic; compliance, regulatory and
litigation matters, including failure to comply with complex legal
and regulatory environments; other financial and economic risks;
and other factors discussed in our Quarterly Report on Form 10-Q
for the third quarter of 2022 and in our Annual Report on Form 10-K
for the year ended December 31, 2021, including in the section
captioned “Risk Factors.” Forward-looking statements speak only as
of the date on which they are made, and we assume no obligation to
update or revise any forward-looking statements or other
information contained herein, whether as a result of new
information, future events or otherwise. You are cautioned not to
put undue reliance on these forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221114005345/en/
IR Contacts United States: Ran Meir, (267) 468-4072
Israel: Yael Ashman, 972 (3) 914-8262
PR Contacts Kelley Dougherty, (973)-832-2810 Yonatan
Beker, (973) 264-7378
Teva Pharmaceutical Indu... (NYSE:TEVA)
Historical Stock Chart
From Feb 2023 to Mar 2023
Teva Pharmaceutical Indu... (NYSE:TEVA)
Historical Stock Chart
From Mar 2022 to Mar 2023
